Hannah: I came out of the conference feeling extremely excited about all the gene editing clinical applications that are not going to involve embryos. Devlin: There are definitely a lot of lingering questions about access and about how these therapies are going to be made available to everyone, not just our reported people. And this is why sort of turning Harry and Megan into polarizing figures ticks a lot of boxes because it just drives clicks. Rihanna rocks off at about one. She just swans in like she's the most ordinary person in the world just wanting a couple of minutes late. Chante Joseph: Two weeks later, I'm sliding down the wall crying. One week later, I mess with
Ian Sample speaks to Guardian science correspondent Hannah Devlin about the latest developments and debates about gene editing to emerge from a summit at the Francis Crick Institute in London. The summit heard from the first person with sickle cell disease to be treated with a technique known as Crispr. He also hears from Prof Claire Booth about ensuring these cutting edge treatments are made available to everyone who needs them. Help support our independent journalism at
theguardian.com/sciencepod